tesnatilimab

A recombinant human immunoglobulin G4 (IgG4) monoclonal antibody against the immune activating receptor natural-killer group 2, member D receptor protein (NKG2D or KLRK1), with potential immunomodulating and anti-inflammatory activities. Upon administration, tesnatilimab targets and binds to NKG2D expressed on human natural killer (NK) and certain T lymphocytes, and blocks the activation of NKG2D. This may inhibit both the cytotoxic activities of lymphocytes and the production of pro-inflammatory cytokines. NKG2D, a dimeric, type II transmembrane protein expressed on human NK and certain T cells, and its ligands play important roles in some inflammatory and autoimmune conditions.